Healix Infusion Therapy, Inc

Healix Infusion Therapy, Inc. is a U. S. -based provider specializing in comprehensive infusion management services and pharmaceutical solutions for outpatient therapies, primarily serving healthcare practitioners and patients requiring complex treatment.

Healix Infusion Therapy, Inc. was founded in 1989 and is headquartered in Sugar Land, US. The company focuses on managing outpatient infusion therapies. Derek Larson is the founder and has previously engaged in other ventures.

The firm received a significant investment from TA Associates in December 2017, targeting its infusion management services. Healix has executed a total of 1 deal as of the last reported date. Healix, LLC specializes in comprehensive infusion management services and related pharmaceutical solutions. Their core offerings include the management of outpatient infusion therapies, a network of accredited ambulatory infusion centers, and pharmacy services that provide patient-specific injectable and infusion medications.

Additionally, Healix operates a HUB service that facilitates patient access to therapies requiring specialized support, enhancing communication between patients and healthcare providers. The company primarily serves healthcare practitioners, including physicians and hospital systems, and supports patients requiring intravenous or injection therapies, particularly in oncology and chronic disease management. Healix’s products and services are provided across various geographical markets in the United States, ensuring a wide reach within the healthcare landscape. Healix generates revenue through a multifaceted business model that encompasses direct partnerships with healthcare providers and institutions.

The company's transactions are structured predominantly as B2B agreements, where providers partner with Healix to utilize its infusion management services, pharmacy offerings, and patient support systems. Revenue streams are supplemented by fees for the distribution of pharmaceuticals and the provision of specialized HUB services. Healix’s pricing structures reflect the complexity and customization of services offered to clients, ensuring that both standard and specialized treatment solutions are accessible to their patients. This approach allows Healix to maintain a sustainable financial model while enhancing patient outcomes through tailored healthcare solutions.

Looking ahead, Healix Infusion Therapy, Inc. is focused on expanding its range of services and entering new markets. The company plans to develop and launch new products aimed at improving infusion therapy management, although specific release dates have not been disclosed. Geographic expansion is targeted towards additional U.

S. regions, enhancing its service capabilities. The recent investment from TA Associates in December 2017 will support these initiatives, enabling Healix to bolster its operational infrastructure and increase its market presence.